Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK Tdap Vaccine vs Td in Adolescents
NCT00109330Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2002
- Primary completion
- Apr 2004
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) in diphtheria, Tetanus, pertussis, sponsored by GSK. Started Nov 2002; status: completed.
02
Drugs
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT00109330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109330.